High Dose Chemo With Stem Cell Transplant as Treatment for Multiple Sclerosis That Failed Prior Treatment

Stopped early · Phase 2

Conditions studied: Multiple Sclerosis

In brief

The purpose of this study is to evaluate the toxicity and the effectiveness of high dose chemotherapy with HPC transplant Multiple Sclerosis that has failed at least two lines of therapy

Key facts

Study ID

NCT01679041

Run by

Seah Lim M.D.

People needed

1

Starts

2012-11-01

Expected to finish

2013-11-01

Last updated by the study team

2013-11-25

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age between 18-60, inclusive
• Patients carry a diagnosis of multiple sclerosis, according to the McDonald's criteria for diagnosis (Polman et al, 2011).
• Must have a neurologist providing the primary care for the MS and be willing to be evaluated for the multiple sclerosis by the two neurologists who are the co-investigators in the protocol.
• Must be documented to be HIV negative.
• An EDSS of 3.5 - 5.5
• Patients must be able to give written consent.
• Inflammatory disease despite primary disease modifying therapy with at least 6 months of interferon and another disease modifying therapy, including fingolimod,glativamir, natalizumab, and mitoxantrone. Failure is defined as two or more clinical relapses with documented neurologic changes (excluding sensory changes) within the year prior to the study. (NOTE: Relapses must have required treatment with corticosteroids). Failure may also be defined as one relapse (excluding sensory changes) treated with methylprednisone and, on a separate occasion within the previous 12 months, evidence of active inflammation (i.e. gadolinium enhancement on MRI scan of the CNS).
• No previous history of allergic reaction to cyclophosphamide, G-CSF or mesna
• Patients must not be pregnant
• Failure to accept or comprehend irreversible sterility as a potential side effect of therapy.
• Life expectancy of more than 6 months
• No evidence of myelodysplastic syndrome on peripheral blood smear
• Not allergic to cyclophosphamide, mesna, fludarabine or alemtuzumab
• Baseline serum creatinine must be <1.5 mg/dL, left ventricular ejection fraction >55%, adequate pulmonary functions (oxygen saturation at room air of >90%), and AST and ALT not > 2x upper limits of normal, and no history of previous or active malignancy, except for localized cutaneous basal or squamous cell carcinoma in situ of the cervix.

You may not qualify if…

• Diagnosis of primary progressive MS.

Where it is running

• Amarillo Diagnostic Clinic — Amarillo, Texas, United States
• Dr Ruby Saulog — Amarillo, Texas, United States
• Texas Oncology — Amarillo, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.